Letter to the Editor

Oxcarbazepine Treatment of Refractory Bipolar Illness

Authors: Tricia G. Majczenko, MD, Jonathan T. Stewart, MD

Abstract

To the Editor:


Numerous studies over the past 25 years have demonstrated the efficacy of carbamazepine in bipolar illness.1 Unfortunately, carbamazepine can be a difficult medication to use, due to significant drug-drug interactions, laborious titration related to enzyme autoinduction (both due to induction of the cytochrome P450 system), potential for agranulocytosis and hyponatremia.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hirschfeld RMA, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004;7:507–522.
 
2. Bazil CW. Antiseizure drugs. In Noseworthy JH (ed). Neurological Therapeutics: Principles and Practice. London, Martin Dunitz, 2003; pp. 297–307.
 
3. Emrich HM, Altmann H, Dose M, et al. Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983;19:369–372.
 
4. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243–250.
 
5. Emrich HM. Studies with (Trileptal) oxcarbazepine in acute mania. Int Clin Psychopharmacol 1990;5:83–88.